Background Patients treated with methotrexate for rheumatoid arthritis often improve but
continue to have active disease. This study was undertaken to determine whether the addition …

Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease…

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis),
evaluated the safety and efficacy of adalimumab (Humira), a fully human monoclonal …

Objective To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n = 637) …

Objective To evaluate the safety of anakinra (a recombinant human interleukin‐1 receptor
antagonist) in a large population of patients with rheumatoid arthritis (RA), typical of those …

Objectives Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA). Methods
Pooled observed case analysis of data from patients with moderate-to-severe, active RA …

Background Although opioid analgesics have well-defined efficacy and safety in treatment
of chronic cancer pain, further research is needed to define their role in treatment of chronic …